

# REDEFINING PERSONALIZED MEDICINE ACROSS THE CANCER CARE CONTINUUM

EXACT SCIENCES IS CHANGING THE WAY WE THINK ABOUT DETECTING AND TREATING CANCER. AS A LEADER IN CANCER TESTING, WE ARE COMMITTED TO PROVIDING LIFE-CHANGING TREATMENT GUIDANCE.

**EXACT  
SCIENCES**

The Oncotype® portfolio of tests delivers clinically significant genomic intelligence at all stages of cancer.



**>1 million** patients benefited<sup>1</sup>



**>20 years** committed to precision oncology



**>90 countries** served



**>125 clinical studies** performed



**>\$5 billion** saved

# SMART CANCER CARE TO OPTIMIZE TREATMENT DECISIONS



Every cancer is unique and affects each person differently. Oncotype® tests give you the information you need to address the individual biology of each patient's tumor.

For your patients with **EARLY-STAGE CANCER**

## EARLY STAGE, ER+, HER2- BREAST CANCER

The only genomic test proven to predict a patient's individual benefit from chemotherapy

*oncotypeDX*<sup>®</sup>  
*Breast Recurrence Score*

## DUCTAL CARCINOMA IN SITU

A genomic test to quantify the risk of local recurrence (DCIS or invasive) in ductal carcinoma *in situ*

*oncotypeDX*<sup>®</sup>  
*Breast DCIS Score*

## LOCALIZED PROSTATE CANCER

A genomic test to help inform whether to treat in the low-risk setting and how to treat in the high-risk setting

*oncotypeDX*<sup>®</sup>  
*Genomic Prostate Score*

## ANATOMIC STAGE II, MMR-P, AND STAGE III A/B COLON CANCERS

A genomic test that quantifies the risk of recurrence, for insight beyond traditional measures

*oncotypeDX*<sup>®</sup>  
*Colon Recurrence Score*

For your patients with **ADVANCED CANCER**

## ADVANCED CANCERS

Rapid comprehensive genomic profiling to aid therapy selection in advanced cancer

*oncotypeMAP*<sup>™</sup>  
*Pan-Cancer Tissue*

## mCRPC AFTER AR-TARGETED THERAPY FAILURE

The first and only predictive and prognostic test to guide decisions between AR-targeted therapy and chemotherapy

*oncotypeDX*<sup>®</sup>  
*AR-V7 Nucleus Detect*  
powered by Epic Sciences

No matter where your patients are on their cancer journey, there is an Oncotype test to deliver clear, actionable results.

# HELPING YOU TO OPTIMIZE YOUR TREATMENT DECISIONS FOR YOUR PATIENTS

As a leader in genomic testing for more than 20 years, Exact Sciences is committed to supporting you and your patients.



Easy ordering through one convenient physician portal for all Oncotype® tests



Clear, simple reports with actionable results to help inform treatment decisions



Fast and relevant answers integrated within your existing workflow



All Oncotype tests are covered by Medicare and many commercial insurance plans



Exact Sciences supports patient access and offers financial assistance through the Genomic Access Program (GAP)

Get answers to your billing questions at [oncotypeiq.com/billing](https://oncotypeiq.com/billing)

“ We’re committed to providing earlier answers and life-changing treatment guidance to support patients along every step of their cancer journey. ”

—Kevin Conroy, CEO and President of Exact Sciences

---

Order Oncotype tests through the online physician portal or by calling **866 ONCOTYPE (866-662-6897)**.

---

**Reference: 1.** Exact Sciences. Data on File. 2021.

AR-V7 Nucleus Detect, Breast Recurrence Score, Colon Recurrence Score, DCIS Score, Genomic Prostate Score, Oncotype, Oncotype DX, Oncotype MAP, and Recurrence Score are trademarks of Genomic Health, Inc. Exact Sciences is a registered trademark of Exact Sciences Corporation. ©2021 Genomic Health, Inc. All rights reserved. EXS13009\_0521

EXACT SCIENCES CORPORATION  
5505 Endeavor Lane, Madison, WI 53719  
ExactSciences.com | ExactLabs.com | 1-844-870-8870

**EXACT  
SCIENCES**